Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

BACKGROUND: Docetaxel monotherapy is one of the standard treatments for non-small-cell lung cancer in elderly patients. The addition of bevacizumab to docetaxel seems promising; however, the feasibility of this combination has not been investigated in such patients. METHODS: Patients with advanced n...

Descripción completa

Detalles Bibliográficos
Autores principales: Takagi, Yusuke, Hosomi, Yukio, Oshita, Fumihiro, Okamoto, Hiroaki, Seki, Nobuhiko, Minato, Koichi, Aono, Hiromi, Yamada, Kouzo, Okuma, Yusuke, Hida, Naoya, Sakamoto, Takahiko, Miura, Yosuke, Yomota, Makiko, Satoh, Akira, Kunitoh, Hideo, Sakamaki, Kentaro, Shibuya, Masahiko, Watanabe, Koshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612532/
https://www.ncbi.nlm.nih.gov/pubmed/26481215
http://dx.doi.org/10.1186/s12885-015-1756-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612532/
https://www.ncbi.nlm.nih.gov/pubmed/26481215
http://dx.doi.org/10.1186/s12885-015-1756-1

Ejemplares similares